Synergistic Cytotoxicity of Melatonin and New-generation Anticancer Drugs Against Leukemia Lymphocytes But Not Normal Lymphocytes - PubMed (original) (raw)
Comparative Study
. 2017 Jan;37(1):149-159.
doi: 10.21873/anticanres.11300.
Affiliations
- PMID: 28011485
- DOI: 10.21873/anticanres.11300
Comparative Study
Synergistic Cytotoxicity of Melatonin and New-generation Anticancer Drugs Against Leukemia Lymphocytes But Not Normal Lymphocytes
Zhivko Zhelev et al. Anticancer Res. 2017 Jan.
Abstract
The present study demonstrates specific sensitization of leukemia lymphocytes towards anticancer drugs using melatonin and clarifies the role of reactive oxygen species (ROS) for induction of apoptosis. The study covers four conventional and 11 new-generation anticancer drugs. Four parameters were analyzed simultaneously in leukemia and normal lymphocytes treated with drug, melatonin, or their combination: cell viability, induction of apoptosis, level of reactive oxygen species (ROS), and level of protein-carbonyl products. Almost all investigated combinations of melatonin with new-generation anticancer drugs were characterized by synergistic cytotoxicity towards leukemia lymphocytes, while the combinations with conventional drugs exhibited additive or antagonistic effects on cell viability. In leukemia lymphocytes, the additive cytotoxicity of doxorubicin plus melatonin was accompanied by low levels of ROS and protein-carbonyl products, as well as by suppression of apoptosis. In normal lymphocytes, none of the studied parameters changed significantly compared to cells treated with doxorubicin only. The combinations of everolimus plus melatonin and barasertib plus melatonin exhibited impressive synergistic cytotoxic effects on leukemia lymphocytes but did not affect the viability of normal lymphocytes. In leukemia cells, the synergistic cytotoxicity was accompanied by strong induction of apoptosis but a decrease of ROS to a level below that of the control. In normal lymphocytes, these combinations did not affect the level of ROS nor of protein-carbonyl products, and did not induce apoptosis. The data suggest that melatonin is a promising supplementary component in chemotherapy which allows the therapeutic doses of anticancer drugs to be reduced, minimizing their side-effects.
Keywords: Melatonin; anticancer drugs; apoptosis; leukemia lymphocytes; normal lymphocytes; reactive oxygen species.
Copyright© 2017 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.
Similar articles
- Inhibition of the Pentose-phosphate Pathway Selectively Sensitizes Leukemia Lymphocytes to Chemotherapeutics by ROS-independent Mechanism.
Zhelev Z, Ivanova D, Bakalova R, Aoki I, Higashi T. Zhelev Z, et al. Anticancer Res. 2016 Nov;36(11):6011-6020. doi: 10.21873/anticanres.11190. Anticancer Res. 2016. PMID: 27793928 - Vitamins C and K3: A Powerful Redox System for Sensitizing Leukemia Lymphocytes to Everolimus and Barasertib.
Ivanova D, Zhelev Z, Lazarova D, Getsov P, Bakalova R, Aoki I. Ivanova D, et al. Anticancer Res. 2018 Mar;38(3):1407-1414. doi: 10.21873/anticanres.12364. Anticancer Res. 2018. PMID: 29491065 - Redox Control in Acute Lymphoblastic Leukemia: From Physiology to Pathology and Therapeutic Opportunities.
Chen Y, Li J, Zhao Z. Chen Y, et al. Cells. 2021 May 17;10(5):1218. doi: 10.3390/cells10051218. Cells. 2021. PMID: 34067520 Free PMC article. Review. - Mitochondria as emerging targets for therapies against T cell acute lymphoblastic leukemia.
Olivas-Aguirre M, Pottosin I, Dobrovinskaya O. Olivas-Aguirre M, et al. J Leukoc Biol. 2019 May;105(5):935-946. doi: 10.1002/JLB.5VMR0818-330RR. Epub 2019 Jan 30. J Leukoc Biol. 2019. PMID: 30698851 Review.
Cited by
- Melatonin as a regulator of apoptosis in leukaemia: molecular mechanism and therapeutic perspectives.
Mafi A, Rismanchi H, Gholinezhad Y, Mohammadi MM, Mousavi V, Hosseini SA, Milasi YE, Reiter RJ, Ghezelbash B, Rezaee M, Sheida A, Zarepour F, Asemi Z, Mansournia MA, Mirzaei H. Mafi A, et al. Front Pharmacol. 2023 Aug 14;14:1224151. doi: 10.3389/fphar.2023.1224151. eCollection 2023. Front Pharmacol. 2023. PMID: 37645444 Free PMC article. Review. - Melatonin protects against apoptosis of megakaryocytic cells via its receptors and the AKT/mitochondrial/caspase pathway.
Yang M, Li L, Chen S, Li S, Wang B, Zhang C, Chen Y, Yang L, Xin H, Chen C, Xu X, Zhang Q, He Y, Ye J. Yang M, et al. Aging (Albany NY). 2020 Jul 10;12(13):13633-13646. doi: 10.18632/aging.103483. Epub 2020 Jul 10. Aging (Albany NY). 2020. PMID: 32651992 Free PMC article. - Melatonin Improves Quality of Repeated-Poor and Frozen-Thawed Embryos in Human, a Prospective Clinical Trial.
Bao Z, Li G, Wang R, Xue S, Zeng Y, Deng S. Bao Z, et al. Front Endocrinol (Lausanne). 2022 May 13;13:853999. doi: 10.3389/fendo.2022.853999. eCollection 2022. Front Endocrinol (Lausanne). 2022. PMID: 35634513 Free PMC article. Clinical Trial. - Targeting mTOR in Acute Lymphoblastic Leukemia.
Simioni C, Martelli AM, Zauli G, Melloni E, Neri LM. Simioni C, et al. Cells. 2019 Feb 21;8(2):190. doi: 10.3390/cells8020190. Cells. 2019. PMID: 30795552 Free PMC article. Review. - Field rates of Sivanto™ (flupyradifurone) and Transform® (sulfoxaflor) increase oxidative stress and induce apoptosis in honey bees (Apis mellifera L.).
Chakrabarti P, Carlson EA, Lucas HM, Melathopoulos AP, Sagili RR. Chakrabarti P, et al. PLoS One. 2020 May 21;15(5):e0233033. doi: 10.1371/journal.pone.0233033. eCollection 2020. PLoS One. 2020. PMID: 32437365 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources